Why Ovid Therapeutics Inc.’s (OVID) Stock Is Down 5.91%
As of Friday, October 23, Ovid Therapeutics Inc.’s OVID share price has dipped by 5.91%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Commentary & Analysis
Why Ovid Therapeutics Inc.’s (OVID) Stock Is Up 11.65%
As of Wednesday, October 21, Ovid Therapeutics Inc.’s OVID share price has surged by 11.65%, which has investors questioning if this is right time to sell.Michael Rose
Why Ovid Therapeutics Inc.’s (OVID) Stock Is Up 11.52%
As of Tuesday, October 20, Ovid Therapeutics Inc.’s OVID share price has surged by 11.52%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Ovid Therapeutics Inc.’s (OVID) Stock Is Down 5.09%
As of Friday, October 16, Ovid Therapeutics Inc.’s OVID share price has dipped by 5.09%, which has investors questioning if this is right time to buy.Michael Rose
Why Ovid Therapeutics Inc.’s (OVID) Stock Is Down 6.02%
As of Tuesday, October 13, Ovid Therapeutics Inc.’s OVID share price has dipped by 6.02%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | OVID | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $421.8 | $229.7 | 36% |
|
| Shares Out (Mil) | 197.5 | 53.4 | 76% |
|
| Institutional Ownership | 97.0% | 92.9% | 72% |
|
| Float (Mil) | 163.4 | 41.7 | 70% |
|
| Beta | 0.25 | 0.95 | 15% |
|
| Avg Daily Volume (000s) | 2,031 | 520 | 82% |
|
| Price Change (52-week) |
34.2% | 46.5% | 78% |
|
| Growth | OVID | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (10.3%) | 13.2% | 5% |
|
| Net Income (5yr) | 26.5% | (10.1%) | 82% |
|
| EPS (5yr) | 30.1% | 15.8% | 81 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.6%) | (15.7%) | 36% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 9 | 9 | |
| Current EPS | ($0.084) | ($0.362) | ($0.367) | |
| Month Ago EPS | ($0.089) | ($0.374) | ($0.387) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.106) | ($0.440) | ($0.452) | |
| Year/Year Chg | 10.5% | 56.0% | 45.3% | |
| Financials | OVID | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $37 | 3% |
|
| Net Income (TTM) (Mil) | ($35) | ($44) | 20% |
|
| EPS (TTM) | ($0.284) | ($1.600) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($55) | ($33) | 9% |
|
| Net Cash Flow (TTM) (Mil) | ($17) | $2 | 27% |
|
| Long-Term Debt (Q1) (Mil) | $11 | $4 | 29% |
|
| Enterprise Value (Q1) (Mil) | $312 | $175 | 30% |
|
| Valuation | OVID | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.89 | 2.17 | 51% |
|
| P/E | na | 20.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | OVID | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 66.5% | 96% |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (22.3%) | (47.2%) | 19% |
|
| ROE | (26.0%) | (53.5%) | 21% |
|
| Liabilities to Assets | 9.5% | 29.4% | 6% |
|
| F-Score | 2 | 2 | 7% |
|
Ovid Therapeutics Inc. did not pass any screens on 10/23/2026.
